

## **Product datasheet for TL502423**

## 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436

OriGene Technologies, Inc.

Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## Wnt5a Mouse shRNA Plasmid (Locus ID 22418)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** Wnt5a Mouse shRNA Plasmid (Locus ID 22418)

**Locus ID:** 22418

Synonyms: 8030457G12Rik; Wnt-5a

**Vector:** pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

Components: Wnt5a - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 22418).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: BC018425, NM 001256224, NM 009524, NM 009524.1, NM 009524.2, NM 009524.3,

NM 001256224.1, NM 001256224.2, NM 009524.4

UniProt ID: P22725

**Summary:** Ligand for members of the frizzled family of seven transmembrane receptors

(PubMed:17117926). Can activate or inhibit canonical Wnt signaling, depending on receptor context (PubMed:16602827). In the presence of FZD4, activates beta-catenin signaling. In the

presence of ROR2, inhibits the canonical Wnt pathway by promoting beta-catenin

degradation through a GSK3-independent pathway which involves down-regulation of beta-catenin-induced reporter gene expression (PubMed:16602827). Suppression of the canonical

pathway allows chondrogenesis to occur and inhibits tumor formation. Stimulates cell migration (PubMed:17117926). Decreases proliferation, migration, invasiveness and clonogenicity of carcinoma cells and may act as a tumor suppressor. Mediates motility of melanoma cells (By similarity). Required during embryogenesis for extension of the primary

anterior-posterior axis and for outgrowth of limbs and the genital tubercle

(PubMed:10021340). Inhibits type II collagen expression in chondrocytes (By similarity).

[UniProtKB/Swiss-Prot Function]





shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. If you need a special design or shRNA sequence, please utilize our <a href="mailto:custom shRNA service">custom shRNA service</a>.

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).